X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, which is indicated for the treatment of Vaginal candidiasis.
Lead Product(s): Fluconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Diflucan-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
ANI Pharmaceuticals acquired Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg. Fluconazole Tablets USP is indicated for the treatment of vaginal candidiasis (vaginal yeast infections due to Candida) and oropharyngeal and esophageal candidiasis.
Lead Product(s): Fluconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
